ANNA KIELAK: Open Payments
NPI 1952750671 · POULSBO, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,415 in 68 payments from 16 companies in 2025. Trend: 2023 $1,589 · 2024 $1,810 · 2025 $1,415
Food & beverage: $1,415
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $357 |
| Alkermes, Inc. | 10 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $164 |
| Otsuka America Pharmaceutical, Inc. | 9 | $153 |
| E.R. Squibb & Sons, L.L.C. | 5 | $143 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $70 |
| Janssen Pharmaceuticals, Inc | 3 | $67 |
| Neurocrine BioSciences, Inc. | 3 | $57 |
| Tris Pharma Inc | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
Products named: VRAYLAR, REXULTI, TRINTELLIX, LYBALVI, COBENFY, CAPLYTA, SPRAVATO, INGREZZA.
Industry payments across WA — which companies pay providers there.
